CTLA4 and urinary bladder cancer: Combination therapy comprising the oncolytic New Castle Disease Virus and a concurrently administered murine‐specific checkpoint inhibitor‐induced abscopal effect on the untreated tumor in a mouse model of bladder cancer.29 On days 7, 9, 11, and 13 after MD49 bladder tumor cells were injected into the flanks of C57BL/6J mice, the right flank tumors were treated with NDV (107 pfu) and the animals concurrently received systemically (intraperitoneally) the anti‐PD‐L1 or anti‐CTLA‐4 antibodies.